Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iodine-131-SGMIB anti-HER2 monoclonal antibody

Drug Profile

Iodine-131-SGMIB anti-HER2 monoclonal antibody

Alternative Names: 131I-SGMIB anti-HER2-VHH1; [131I]-SGMIB Anti-HER2 VHH1; CAM-H2; CAM-H2-I131; Iodine-131-SGMIB anti-HER2 VHH1

Latest Information Update: 17 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Camel-IDS
  • Developer Precirix
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Immunomodulators; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Gastric cancer; Oesophageal cancer

Most Recent Events

  • 04 May 2021 Phase-I/II clinical trials in Breast cancer (Late-stage disease, Second-line therapy or greater) in Canada (IV) (NCT04467515)
  • 04 May 2021 Phase-I/II clinical trials in Gastric cancer (Late-stage disease, Second-line therapy or greater) in Canada (IV) (NCT04467515)
  • 29 Apr 2021 Phase-I/II clinical trials in Oesophageal cancer (Late-stage disease, Second-line therapy or greater) in Canada (IV) (NCT04467515)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top